Immunocore(US:IMCR) Globenewswire·2026-01-09 12:00Core Insights - Immunocore has outlined its strategic priorities for 2026, focusing on expanding its melanoma franchise and advancing its clinical pipeline in oncology, infectious diseases, and autoimmune diseases [2][4][5] Group 1: Melanoma Franchise - The company aims to grow KIMMTRAK (tebentafusp) and prepare for new melanoma indications, targeting more metastatic uveal melanoma patients through ongoing registrational Phase 3 trials [5][12] - Enrollment completion for the TEBE-AM trial is expected in the first half of 2026, with topline data anticipated as early as the second half of 2026 [3][4][12] - The company is also enrolling a third registrational trial, PRISM-MEL-301, evaluating brenetafusp in first-line melanoma [5][12] Group 2: Broader Oncology Pipeline - Immunocore plans to expand beyond melanoma into other tumor types, with multiple Phase 1 readouts expected in 2026 for its PRAME bispecific candidates, including brenetafusp and IMC-P115C [5][6] - The company is also conducting a Phase 1 dose escalation trial in colorectal cancer with IMC-R117C [6] Group 3: Infectious and Autoimmune Diseases - The company is advancing its infectious disease platform, with ongoing Phase 1 trials for HIV and plans to present additional data in the second half of 2026 [6][9] - Immunocore is set to dose the first patient in a Phase 1 type 1 diabetes trial in the first half of 2026 and will submit a clinical trial application for a second autoimmune candidate in the second half of 2026 [2][13] Group 4: Financial Position - As of December 31, 2025, the company reported a preliminary cash position of approximately $864 million, with final financial results expected in late February 2026 [10]